Yasuhiro Hayashi

发表

Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study

T. Akizawa, Hiroyasu Yamamoto, Takanori Hayasaki, 2021, American Journal of Nephrology.

Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study

T. Akizawa, Hiroyasu Yamamoto, Takanori Hayasaki, 2021, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation

T. Ikeda, S. Miyamoto, S. Ogawa, 2020, Heart and Vessels.

Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis

T. Akizawa, Hiroyasu Yamamoto, Takanori Hayasaki, 2021, Kidney international reports.

Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial

T. Akizawa, Hiroyasu Yamamoto, Takanori Hayasaki, 2021, American Journal of Nephrology.

Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study

Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation

T. Ikeda, S. Miyamoto, S. Ogawa, 2019, Heart and Vessels.

Genome-wide association study identifies a new susceptibility locus in PLA2G4C for Multiple System Atrophy.

Sonja W. Scholz, A. Singleton, Y. Kusakabe, 2023, medRxiv.

Letter in Response to "HIF-Prolyl Hydroxylase Inhibitors: Confirmed Efficacy with Uncertain Safety".

T. Akizawa, Hiroyasu Yamamoto, Takanori Hayasaki, 2021, American journal of nephrology.